Industries > Pharma > Dermatological Drugs Market Forecast 2016-2026

Dermatological Drugs Market Forecast 2016-2026

Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma

PUBLISHED: 27 July 2016
PAGES: 273
PRODUCT CODE: PHA0132
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0132 Categories: ,

What can be expected from the Dermatological Drugs Market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
 
Our 273-page report provides 208 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of the dermatological drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Dermatological Drugs submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis

See detailed profiles or revenue forecasts for some the leading products in the market
How will leading drugs perform to 2026? Our study provides detailed profiles or forecasts revenues for a number of drugs in the dermatological drugs market including:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon

See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• EU5 – Germany, UK, France, Italy and Spain
• China
• Japan
• India
• Russia
• Brazil

Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Dermatological Drugs Market will reach $39.26bn in 2026. We predict a high revenue growth over the forecast period driven by an aging population, increasing patient expectations and a higher incidence of skin conditions, rapid growth of emerging economies and emerging dermatological drug technologies.

Our work analyses the key companies in the market. See Visiongain’s analysis of six leading companies, including these:
• Galderma (Nestle Skin Health)
• Johnson & Johnson
• AbbVie
• GlaxosmithKline
• Pfizer
• LEO Pharma

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Dermatological Drugs Market Forecast 2016-2026

What issues will affect the dermatological drugs industry?
Our new report discusses issues and events affecting the dermatological drugs market. You will find discussions, including qualitative analyses:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations and invalidations of major drugs
• Launches of new drug categories
• Biosimilar approvals

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma
In summary, our 273-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Dermatological Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading dermatological drugs in the following areas: psoriasis, skin infections, acne and dermatitis.
• Detailed profiles or revenue forecasts to 2026 for 25 of the leading products in the dermatological drugs market – discover prospects for leading dermatological drugs: Humira, Stelara, Enbrel, Remicade Taltz, Otezla, Cosentyx, Cubicin, Zyvox, Valtrex, Canesten, Lamisil, Bactroban, Solodyn, Epiduo, Claravis, Aczone, Differin, Abscorical/Epirus, Ziana, Doryx, Bepanthen/Bepanthol, Protopic, Dermovate and Elocon.
• Revenue forecasts to 2026 for eleven leading national market and one leading regional markets – US, EU5, China, Japan, India, Russia, and Braz.
• Assessment of six leading companies – analysis of products, revenue, mergers & acquisitions, product type and product pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the over the counter medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2016-2026


Download sample pages

Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2016-2026


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories